Sundia congratulates De Novo Pharmatech for SC10914 IND approval in China


In August 2016, De Novo Pharmatech successfully received their first CFDA IND approval for the class 1.1 IND submission (SC10914) for innovative target therapy in oncology. This is a new target therapy co-submitted by De Novo Pharmatech and Qingfeng Pharmaceutics. Sundia is honored to have contributed to and assisted both companies in conducting part of the pre-clinical pharmacodynamics study as well as facilitating the successful on-site verification by the PFDA.

share this